Background: For patients with persistent non-valvular atrial fibrillation (NVAF), chronic anticoagulation has traditionally been the mainstay of therapy. Warfarin and other vitamin K antagonists were the sole choices up until recently. Objective: To evaluate the healthcare effect and safety of patients with persistent with NVAF using Novel oral anticoagulant (NOAC) and those using warfarin group. Patients and Methods: The study consisted of 124 patients with non-rheumatic atrial fibrillation on their anticoagulation drug. Patients were classified into two main groups according to the drug used as an anticoagulant: Group I: 62 patients with non-valvular atrial fibrillation take warfarin drug 39 men and 21 women ranging in age from 40 to 75 years old. Group II: 62 patients with nonvalvular atrial fibrillation take NOAC drugs, 36 men and 25 women of varying ages 40 to 75 years. Results: Thrombotic complications:In NOAC group I: there were 5 cases of thrombotic complications per year.In Marivan group II: there were 15 cases of thrombotic complications per year.The net result showed that the incidence rate of occurrence of thrombosis among the marivan group was 25% per year compared to 8.2% in the NOAC group. There was a statistically significant difference between both groups regarding thrombotic complications. The net result showed that the incidence rate of occurrence of thrombosis among the marivan group was 20% per 6 months compared to 8.2% in the Noac group.There was a statistically significant difference between both groups regarding thrombotic complications. Conclusion: Overall evidence indicates that NOACs can be considered a safe and effective alternative to warfarin in these subgroups of patients.